The CRE Finance Council Unveils Its 2025 Class of '20 Under 40'
CREFC celebrates young professionals from lenders, investors, borrowers, legal and accounting firms
NEW YORK, June 6, 2025 /PRNewswire/ -- The CRE Finance Council (CREFC), the trade association that exclusively represents the $6 trillion commercial and multifamily real estate finance industry, unveiled its 2025 class of accomplished '20 Under 40' professionals. The 2025 class will be introduced at CREFC's Annual Conference in New York City.
This year's '20 Under 40' recipients are reshaping commercial real estate (CRE) finance with fresh ideas and innovation. They work with lenders, investors, borrowers, and legal and accounting firms. These young professionals focus on a wide range of commercial properties and support servicers, borrowers, and lenders. They originate loans, structure CMBS transactions, and are involved with loan workouts. Also, this class of '20 Under 40' mentors other young professionals and devotes time to community charities.
"We want to congratulate and welcome members of the 2025 class of '20 Under 40', who will become tomorrow's CRE finance leaders. As professionals, they have come of age in a market that has been challenged by high benchmark and mortgage rates and a wide range of economic uncertainty," said Lisa Pendergast, President and CEO of CREFC.
"We salute this class of talented professionals, many of whom are actively involved with CREFC committees and help shape the development of novel and engaging CREFC programming. Their creative energy, determination, and innovations help ensure the CRE finance industry continues to evolve and meet a variety of challenges as we move forward."
CREFC's annual '20 Under 40' awards are part of an ongoing effort to recognize the next generation of leaders in CRE finance. CREFC's Young Professionals Network offers career development, networking, and educational opportunities for this group of CRE finance professionals.
DANIEL BLAKELY
ALLISON M. BORTNER
Partner
Duane Morris LLP
PATRICK BOYLE
Vice President, Boston Capital Markets
Colliers
ANTHONY CANDELA
Senior Vice President
Slate Asset Management
THOMAS F. DUGAN
Partner
Eversheds Sutherland
EVAN GIBSON
Executive Vice President,
Capital Markets
Merchants Capital
BRANDON HEIM
Principal, Real Estate
Ares Management
RACHEL HUNTER-GOLDMAN
Managing Director
KKR
NITYA KUMAR GOYAL
Partner
Dechert LLP
MICHAEL IANNO
Senior Director, Capital Markets
Walker & Dunlop
EUNI JO
Associate
Cadwalader, Wickersham & Taft LLP
KENNETH KASMIR
Senior Manager
Deloitte & Touche LLP
SOPHIA (XUEFEI) OUYANG
Director
KPMG LLP
CHLOE PARK
Assistant Vice President, CMBS & Real Estate Finance Group
Citibank
CLAYTON ROSS
Director
JLL Capital Markets
JEFFREY SCHWARTZ
Director, Real Estate Sector Coverage
ING
PRERNA SONI
Partner
Gibson, Dunn & Crutcher
STEPHANIE STEIN
Partner
McDermott Will & Emery LLP
MADELINE TRACY
Director, U.S. CRE Finance Group
Barclays
MICHAEL WATSON
Director
SVN
To learn more about this year's '20 Under 40' recipients, click here.
About CREFCThe CRE Finance Council (CREFC) is the trade association for the nearly $6 trillion commercial real estate finance industry with a membership that includes more than 400 companies and 19,000 individuals. Member firms include balance sheet and securitized lenders, loan and bond investors, private equity firms, servicers, rating agencies, and borrowers.
For 30 years, CREFC has promoted liquidity, transparency, and efficiency in the commercial real estate finance markets, and acted as a legislative and regulatory advocate for the industry, playing a vital role in setting market standards and best practices, and providing education for market participants.
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-cre-finance-council-unveils-its-2025-class-of-20-under-40-302475552.html
SOURCE CRE Finance Council
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Yahoo
5 hours ago
- Yahoo
Japanese AI Unicorn Notta Enters Otter AI's Market with Innovative Smart Voice Recorder
Notta Bets Big on AI Agent-Powered Voice Recorder as Hardware-SaaS Convergence Accelerates TOKYO, June 6, 2025 /PRNewswire/ -- As OpenAI's ChatGPT dominates enterprise AI adoption and Google Gemini reshapes how businesses think about AI assistants, Japanese unicorn Notta announced its ambitious push into the U.S. hardware market with the Notta Memo AI Voice Recorder. From Tokyo to Silicon Valley: The Underdog Story Notta's journey reads like a classic tech disruption playbook, albeit with a Japanese twist. Since launching in 2020, the company has quietly built a formidable AI transcription empire, amassing over 10 million users globally and signing up 4,000 enterprise customers. The real validation? A staggering 68% of Japan's Nikkei 225 companies—the country's most elite corporations—have integrated Notta's AI solutions into their workflows. "Most observers underestimate just how competitive the Japanese enterprise market is," explains industry analyst Sarah from TechInsight Research. "If you can win over two-thirds of the Nikkei 225, you've proven enterprise-grade reliability at scale." Notta's 2022 Airgram acquisition was just the opening move—the company believes the real opportunity lies in completely reimagining how voice technology integrates into daily workflows. Security-First Approach Gives Notta Enterprise Edge Unlike many AI startups that retrofit compliance as an afterthought, Notta built enterprise security into its foundation from day one. The company holds ISO/IEC 27001 and SOC 2 Type II certifications—credentials that remain elusive for many competitors still scrambling to meet Fortune 500 requirements. More critically, Notta has secured the regulatory trifecta that unlocks major markets: GDPR compliance for European expansion, HIPAA certification for healthcare disruption, and CCPA adherence for California's privacy-conscious landscape. This compliance-first strategy positions Notta to compete for high-value enterprise contracts that security-conscious organizations won't trust to less mature platforms. Hardware Meets AI: The Five-Platform Ecosystem Play The Notta Memo distinguishes itself in the crowded voice recording market through its unique five-platform ecosystem integration—seamlessly connecting web, iOS, Android, Chrome extension, and the Memo device itself. This comprehensive approach addresses the fragmented user experience that has long plagued the industry. Unlike traditional voice recording solutions that force users to choose between SaaS flexibility and hardware reliability, Notta Memo delivers both. The device features advanced bone-conduction technology for complete phone call recording, intelligent noise reduction for crystal-clear audio capture, and one-tap synchronization with Notta. "We're not just launching another recording device," said Ryan, CEO of Notta. "We're introducing a complete AI-powered voice ecosystem that adapts to how people work and communicate in today's hybrid world. Our hardware becomes an extension of our proven AI platform that has already transformed millions of meetings worldwide." Beyond recording, Notta Memo is your AI-powered agent and centralized knowledge hub—seamlessly integrated across all your workflows. Competitive Positioning in a Dynamic Market Notta enters the US AI transcription market with an integrated approach that combines software and hardware innovation. While the market includes established players like Otter AI in the SaaS space and Plaud AI in hardware solutions, Notta differentiates itself through its comprehensive platform that leverages AI capabilities refined through years of serving millions of global users. The company acknowledges the challenges in competing against established players with loyal American user bases. However, Notta's proven track record of rapid user acquisition and revenue growth in Japan, combined with its technological differentiation, positions it as a formidable new entrant. Market Timing and Strategic Vision Notta's American expansion comes at a pivotal moment in the AI industry. As enterprises increasingly adopt AI agents for productivity enhancement and consumers demand more intelligent, seamless technology experiences, the convergence of AI SaaS and purpose-built hardware represents a natural evolution. The Notta Memo's launch signals more than just product diversification – it represents Notta's vision of AI-native hardware that thinks, learns, and adapts to user needs. This positions the company at the forefront of the next wave of AI innovation, where the distinction between SaaS and hardware dissolves into unified, intelligent experiences. About Notta Notta is the AI unicorn that's redefining how the world captures and understands conversations. Seamlessly integrating advanced SaaS with intelligent hardware, Notta turns conversations from any meeting, call, or discussion into actionable insights. This AI-powered, end-to-end solution captures and structures spoken interactions, creating a centralized knowledge hub. Media Contact: contact@ View original content to download multimedia: SOURCE Notta
Yahoo
6 hours ago
- Yahoo
The Coffee Bean & Tea Leaf® Kicks Off Summer with Bold New Ice Blended® Drink Menu and Refreshing Ube Coconut Lineup
The creators of the original Ice Blended® drink celebrate summer with nostalgic favorites, new modern flavors, and can't-miss, weekly promotions LOS ANGELES, June 6, 2025 /PRNewswire/ -- This summer, The Coffee Bean & Tea Leaf® is taking you on a flavor journey with a menu that blends nostalgia and innovation. Now through August 19, 2025, we're celebrating our legacy as the pioneers of the Ice Blended® drink, with a fresh lineup of drinks that's bound to become your new summer obsession. It all started in 1987, when a barista at Coffee Bean & Tea Leaf crafted the very first Ice Blended® drink, changing the world of coffee forever. Fast forward nearly four decades, and we're still leading the charge with that same spirit of creativity and passion. This summer, we're bringing back the classics—like the Ultimate Cold Brew Ice Blended® drink and CaraMocha Ice Blended® drink—and introducing bold new flavors that perfectly capture the essence of sunny California days. "We're thrilled to continue our legacy as tastemakers while constantly pushing the envelope with new and exciting flavor experiences," said Dee Hadley, Head of Marketing, Americas at The Coffee Bean & Tea Leaf. "We didn't just create the Ice Blended® drink, we started a movement. And now, we're inviting our guests to enjoy the flavors that made us who we are, alongside fresh, seasonal creations that are sure to make summer unforgettable." The summer lineup is all about celebrating the best of both worlds: the time-tested favorites that made us famous, and the bold new twists that keep things exciting. So, whether you're a long-time fan or new to the scene, there's something for everyone to savor. Get ready for a few surprises: The three new Ice Blended® beverages are a delicious mix of the classic and the contemporary, ensuring that each sip is as refreshing as a cool breeze on a hot Los Angeles day. Ready to experience summer in a cup? Head to your local cafe for the three new, bold Ice Blended beverages that build on Coffee Bean and Tea Leaf's legacy as a tastemaker of flavor innovation. The beverages include: Ultimate Cold Brew Ice Blended® Drink: Fan-favorite chocolate-covered espresso beans return in the new Ultimate Cold Brew Ice Blended® drink, delivering bold flavor and unbeatable texture. Finished with chocolate drizzle and whipped cream, it's the perfect caffeinated kick for summer. Want to take it up a notch? Make any drink Ultimate by adding chocolate-covered espresso beans. CaraMocha Ice Blended® Drink: A decadent remix of the beloved Mocha Ice Blended® drink, this version adds rich caramel blended in and drizzled throughout—a delightful evolution of a time-tested favorite. Pure CaraMocha Ice Blended® Drink: A twist on our popular Caramel Ice Blended, made with chocolate powder instead of vanilla for an indulgent, chocolatey sweet treat! Ube Coconut Affogato Ice Blended® Drink: Bright, tropical, and richly creamy, this seasonal sensation blends ube and coconut, crowned with a shot of espresso and a swirl of whipped cream. For those craving a lighter yet equally flavorful refreshment, Coffee Bean & Tea Leaf's new lineup of Ube Coconut beverages also includes the Iced Ube Coconut Cream Vanilla Latte with Boba, Iced Ube Coconut Cream Matcha Latte and Ube Coconut Cream Cap Modifier, for a tropical touch to any drink. To celebrate Coffee Bean & Tea Leaf's tastemaker history, the brand is rolling out exciting promotions all summer long: National Ice Blended Day (June 11): Guests can enjoy a $3 small Ice Blended® drink from 12–6 PM. Throwback Thursdays (June 19 - August 14): Every Thursday, from 12–6 PM, guests can grab a Regular Mocha or Vanilla Ice Blended® drink for just $4 (limit 2 per transaction; paid modifiers not included). Whether you're re-experiencing the Original Ice Blended® drink or trying a tropical twist for the first time, this summer is all about flavor, fun, and frozen memories at Coffee Bean & Tea Leaf. For more information about the new beverages, please visit About The Coffee Bean & Tea Leaf® Founded in Southern California in 1963, The Coffee Bean & Tea Leaf® is a global specialty coffee and tea house that inspires new experiences through our flavors from around the world. We source the finest coffees and teas from local communities and then handcraft every beverage to bring out the freshest flavors. As the creator of The Original Ice Blended®, we continue to innovate to enable people everywhere to enjoy the classics as well as new flavors both in our cafés and at home. Headquartered in Asia and a business of the Jollibee Group of Companies, The Coffee Bean & Tea Leaf passionately operates in more than 1,100 locations, across over 20 countries. For more information, visit View original content to download multimedia: SOURCE The Coffee Bean & Tea Leaf
